Table 1.
Clinical and outcome data in the studied groups.
| DXR groupN = 76 | IDR groupN = 67 | p | |
|---|---|---|---|
| Age (years) median (range) | 34.0 (19.0–57.0) | 35.0 (18.0–58.0) | 0.13 |
| Male/female n | 42/34 | 38/29 | 0.86 |
| BMI (Kg/m2) median (range) | 25.2 (17.3–43.3) | 26.8 (16.5–41.6) | 0.15 |
| Comorbidities n (%) | |||
| Hypertension | 1 (1.3) | 3 (4.5) | 0.25 |
| Diabetes | – | 5 (7.5) | 0.015 |
| Hepatitis C | 2 (2.6) | 5 (7.5) | 0.18 |
| Ischemic heart disease | – | 3 (4.5) | 0.062 |
| Lymphadenopathy n (%) | 32 (42.1) | 29 (43.3) | 0.9 |
| Hepatosplenomegaly n (%) | 34 (44.7) | 35 (52.2) | 0.37 |
| FAB classification n (%) | |||
| M0 | 2 (2.6) | 2 (3.0) | 0.26 |
| M1 | 29 (38.2) | 21 (31.3) | |
| M2 | 18 (23.7) | 25 (37.3) | |
| M4 | 18 (23.7) | 14 (20.9) | |
| M5 | 8 (10.5) | 3 (4.5) | |
| M6 | 1 (1.3) | – | |
| M7 | – | 2 (3.0) | |
| WBCs (× 103/ml) median (range) | 33.65 (1.3–214.0) | 17.0 (1.8–231.0) | 0.28 |
| Hb (gm/dl) median (range) | 7.0 (2.9–12.3) | 7.7 (4.0–11.6) | 0.03 |
| Platelets (× 103/ml) median (range) | 35.0 (2.0–525.0) | 45 (4.0–257.0) | 0.64 |
| Blasts (%) median (range) | 55.5 (10.0 - 99.0) | 48.5 (6.0–95.0) | 0.26 |
| Cytogenetic risk n (%) | |||
| Favorable | 9 (11.8) | 15 (22.4) | 0.17 |
| Intermediate | 44 (57.9) | 38 (56.7) | |
| Adverse | 23 (30.3) | 14 (20.9) | |
| Treatment side effects n (%) | |||
| Neutropenic fever | 76 (100.0) | 67 (100.0) | NA |
| Severe septicemia | 76 (100) | 67 (100.0) | NA |
| Cardiotoxicity | 18 (23.7) | 20 (29.9) | 0.76 |
| Liver dysfunction | 14 (18.4) | 13 (19.4) | 0.86 |
| Renal dysfunction | 10 (13.1) | 3 (4.5) | 0.096 |
| Respiratory dysfunction | 10 (13.1) | 6 (9.0) | 0.38 |
| Complete response n (%) | 51 (67.1) | 46 (68.7) | 0.84 |
| Allogenic stem cell transplantation n (%) | 3 (3.9) | 4 (6.0) | 0.58 |
| Overall non-survivors n (%) | 51 (67.1) | 34 (50.7) | 0.047 |
| 30-day non-survivors | 27 (35.5) | 21 (31.3) | 0.6 |
| 60-day non-survivors | 32 (41.4) | 25 (37.3) | 0.56 |
| DFS (months) median (95.0% CI) | 4.0 (1.02–7.0) | 5.0 (1.34–8.7) | 0.69 |
| OS (months) median (95.0% CI) | 6.0 (2.4–9.6) | 8.0 (3.3–12.7) | 0.29 |
| Cause of death n (%) | |||
| Uncontrolled infection | 32 (42.1) | 20 (29.9) | 0.65 |
| Uncontrolled hemorrhage | 14 (18.4) | 9 (13.4) | |
| Multiple organ failure | 4 (5.3) | 5 (7.5) | |
| Sudden unexpected death | 1 (1.3) | – | |
| Treatment cost/patient (EGP) mean ± SD | 1021.5 ± 254.6 | 4603.8 ± 1196.9 | <0.001 |